MTA1 and Familial prostate cancer: In the intervention strategy with cancer-prone Pten-null mice, in which progressive increase in MTA1 levels were associated with age-related aggressiveness of prostate cancer (Figure 1E), we found a substantial decrease in MTA1 levels in response to pterostilbene treatment at any ages examined by immunoblotting or IHC (Figure 6A and 6C and Supplementary Figure S4).